查看购物车
  • Traditional Chinese
  • English
  • Japanese
生物保存市场－全球及区域分析：按产品类型、应用、最终用户和地区划分－分析与预测（2025-2035）
市场调查报告书
商品编码
1956054

生物保存市场－全球及区域分析：按产品类型、应用、最终用户和地区划分－分析与预测（2025-2035）

Biopreservation Market - A Global and Regional Analysis: Product Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 128 Pages | 商品交期: 1-5个工作天内

价格

预计到 2024 年，全球生物保存市场规模将达到 43.163 亿美元，到 2035 年将显着成长至 151.854 亿美元。

这意味着从 2025 年到 2035 年，复合年增长率将达到 12.61%。

关键市场统计数据
预测期 2025-2035
截至2025年的估值 46.318亿美元
2035 年预测 151.854亿美元
复合年增长率 12.61%

这一增长是由细胞和基因疗法的日益普及、生物样本库和基因库的快速发展以及对用于研究和临床应用的高价值生物材料长期储存日益增长的需求所推动的。

由于生物医学研究、再生医学、临床试验和先进治疗药物生产等领域产生的生物样本数量不断增长，生物保存市场正经历显着的成长动能。这些应用中使用的细胞、组织、血液和遗传物质需要检验的保存方案，以确保其在储存、运输和后续使用过程中保持活性、稳定性和功能完整性。随着个人化医疗、群体基因组学和先进治疗方法的兴起，可靠的生物保存技术已成为支撑不断发展的医疗保健和生命科学生态系统的关键基础架构。

技术创新正在重塑生物保存产业，冷冻保存介质、可控冷冻系统、自动化和机器人辅助的低温储存以及数位化整合监测解决方案的进步，提高了样本品质、扩充性和合规性。儘管成长前景强劲，但该市场仍面临许多挑战，包括高额的资本投资、高能耗的储存系统以及与冷冻库故障和低温供应中断相关的营运风险。然而，对生物银行基础设施、再生医学计画和全球低温运输物流的持续投资预计将在长期内支撑市场扩张。

市场概览

全球生物保存市场已从传统的冷藏方法发展成为一个技术先进的生态系统，支持在研究、临床和商业环境中保存细胞、组织、器官和遗传物质。市场参与企业正致力于开发高性能生物保存培养基、自动化低温储存平台和数位化监控系统，以满足现代生物银行和先进治疗工作流程日益增长的品质、可追溯性和合规性要求。

生物保存解决方案提供者、生物样本库、製药和生物技术公司、合约研发生产机构 (CDMO) 以及学术研究机构之间的策略联盟正在加速整个保存流程的创新和标准化。随着生物样本采集规模和复杂性的不断增长，生物保存正逐渐成为支撑精准医疗、细胞和基因治疗生产以及大规模纵向研究的核心基础设施。这些结构性变化正将生物保存定位为全球生命科学和医疗保健生态系统中的关键成长市场。

对产业的影响

受细胞和基因疗法快速发展、大规模生物银行库建设以及对高价值生物样本长期保存需求日益增长的推动，全球生物保存市场正经历着显着的产业变革。生物保存培养基、低温储存系统、自动化平台和低温运输物流等关键产业领域的参与企业，在确保用于研究、临床试验和商业生产的细胞、组织、血液和遗传物质的可靠保存方面发挥着核心作用。这些解决方案对于细胞和基因疗法开发、再生医学、生物银行和精准医疗等应用至关重要，因为解冻后样本的活性、功能和完整性直接影响后续处理的结果。

冷冻保存介质、可控冷冻技术、自动化和机器人冷冻保存系统以及数位化整合监测系统的进步，正在提高营运效率、减少样本损失并加强监管合规性。生物保存技术透过在全球研发和生产网路中实现一致的存储，支持可扩展的临床开发、分散式治疗药物生产和长期纵向研究。该市场与个人化医疗和先进疗法的契合进一步放大了其产业影响力，使生物保存技术成为支持下一代生命科学创新和医疗保健服务的基础基础设施。

市场区隔:

细分1：按产品

  • 培养基
  • 装置

培养基细分市场在生物保存市场（按产品划分）主导

根据产品类型，培养基预计将在生物保存市场中占据主导地位。由于其在维持生物材料（包括细胞、组织、遗传物质以及用于细胞和基因治疗、生物生物银行和再生医学的生物製药）的活力、稳定性和功能完整性方面发挥着至关重要的作用，预计培养基将占据相当大的市场份额。随着生物技术和生物製药行业的持续扩张，由于细胞疗法和再生医学的快速发展，对高性能生物保存培养基的需求也在稳步增长。 CAR-T疗法和干细胞疗法等先进治疗方法高度依赖冷冻保存技术，以在生产、储存和运输过程中维持细胞品质。值得注意的是，大多数获得FDA已通过核准的细胞和基因疗法都依赖冷冻保存的原料或最终产品，这凸显了优化解冻后细胞活力和功能的重要性。

细分 2：按应用

  • 研究用途
  • 治疗用途
  • 其他的

预计科研应用将主导生物保存市场（按应用领域划分）。

预计研究应用将推动生物保存市场的发展，其驱动力包括生物医学和基因组学研究的日益增长、生物样本库的快速扩张以及临床试验和药物研发活动的活性化。在研究环境中，生物保存培养基和保存系统对于维持生物材料在长期储存、运输和重复实验使用过程中的活性、稳定性和分子完整性至关重要。例如，在干细胞研究中，人类多功能细胞（hPSCs）通常使用专门的生物保存培养基进行保存，以维持其多功能和分化潜能，即使在解冻后也能如此，这对于再生医学和发育生物学研究至关重要。同样，在基因组学和人群研究中，大型生物样本库依赖检验的生物保存解决方案来保存DNA、RNA、组织和细胞，从而确保样本的一致性并适用于纵向研究。随着全球调查计画的扩展，数据可重复性和样本品质变得越来越重要，研究应用中对可靠的生物保存解决方案的需求依然强劲，这巩固了该领域在生物保存市场的主导地位。

细分3：按最终用户

  • 生物样本库和基因库
  • 医院
  • 製药和生物技术公司
  • 受託研究机构（CRO）
  • 其他（私人诊所、学术机构、政府机构）

生物样本库和基因库将推动生物保存市场（按最终用户划分）的发展。

由于生物样本库和基因库在基因组研究、药物发现、临床试验和个人化医疗中发挥核心作用，预计它们将推动生物保存市场的发展。这些机构负责长期保存高价值生物材料，包括细胞、组织、血液和遗传样本，这些材料是疾病研究、生物标记鑑定和治疗方法开发的基础。基因测序、人群调查和生物技术研究的快速发展显着增加了对可靠生物保存解决方案的需求，这些解决方案能够长期维持样本的完整性、活性和分子稳定性。此外，来自政府、研究联盟和私人机构的持续投资正在推动全球生物样本库和基因库的扩张，为再生医学计画、大规模流行病学研究和多中心临床试验提供支援。随着这些样本库规模和复杂性的不断增长，对高品质生物保存培养基、低温储存系统和监测基础设施的需求也在稳步增长。

细分 4：按地区

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 其他地区

北美地区在生物保存市场中处于领先地位（按地区划分）。

全球生物保存市场正经历强劲成长，这主要得益于细胞和基因疗法研发管线的不断扩展、大规模生物银行库建设以及对高价值生物材料长期储存需求的日益增长。北美预计将继续保持领先地位，这得益于其先进的医疗和研究基础设施、细胞和基因疗法的早期应用以及对生物样本库和再生医学的大量投资。预计到2035年，该地区的市场规模将达到62.433亿美元，主要由对生物保存培养基、低温储存系统和符合GMP标准的低温运输服务的持续需求所驱动。北美的主导地位也得益于众多大型生物技术和製药公司、成熟的学术和临床研究机构以及支持先进治疗方法的健全法规结构。此外，临床试验的增加、细胞和基因疗法（CGT）的商业化以及国家和私人生物银行计画的不断扩展，持续推动对可靠且扩充性的生物保存解决方案的长期需求，从而巩固了该地区的市场主导地位。

生物保存市场最新趋势

  • 2025年11月，BioLife Solutions公司开设了艾比·J·马修斯生物保护卓越中心。该中心位于公司位于博塞尔的扩建总部内，以公司创始成员、执行副总裁兼首席科学官艾比·J·马修斯博士的名字命名。
  • 2025年10月，Cryoport在法国罗浮宫开设了一座占地55,000平方英尺的全新全球供应链中心。该中心地理位置位置，毗邻戴高乐机场，将协助先进疗法的全球分销。这座先进的设施提供端到端的温控供应链解决方案，为生技药品和其他温度敏感型材料带来无与伦比的便利性和可靠性。
  • 2025年4月，BioLife Solutions, Inc.收购了Pantera Cryosolutions, Inc.（简称「Pantera」），后者是一家私人企业，致力于开发基于其专有「冰重结晶抑制剂（IRI）」技术的先进冷冻保存解决方案。此次收购进一步巩固了BioLife在生物保存领域的领先地位，拓展了其耗材解决方案产品组合，并为经营团队注入了宝贵的科学专业知识。

需求——驱动因素、挑战与机会

市场驱动因素

细胞和基因治疗及再生医学的快速发展—细胞和基因治疗（CGT）以及再生医学的快速发展是生物保存市场的主要结构性驱动因素。根据国际细胞和基因治疗学会（ISCT）发布的《2024年全球监管报告》，目前全球有超过3000个CGT计画正在研发中，后期临床试验活动和监管核准不断增加。这些治疗方法在整个价值链中高度依赖冷冻保存材料，包括白血球分离术、基因修饰细胞中间体、病毒载体、细胞库和冷冻最终药物产品。同行评审的研究表明，冷冻保存的原料（例如白血球分离术材料）在解冻后可保持90%以上的细胞活力，同时功能性能与新鲜材料相当，这证明冷冻保存是一种不逊色且可扩展的方法。细胞生长激素（CGT）产量的增加和商业化的加​​速推进，带动了对高性能冷冻保存介质、可控冷冻技术、自动化低温储存、超低温和液态氮平台以及符合GMP标准的低温运输物流的需求。这项变革正将生物保存技术转变为支援CGT开发、生产和全球分销的核心平台。

市场挑战

先进生物保存基础设施的高昂购买和营运成本——高昂的购买和营运成本仍然是生物保存市场的主要阻碍因素，尤其是在先进的低温储存基础设施方面。超低温冷冻库、液态氮储存系统、可控冷冻设备和监控基础设施都需要大量的初始投资和持续的维护。超低温冷冻库的能耗极高，每天耗电高达20千瓦时，导致每年的电力和空调成本居高不下，对于大型设施而言更是如此。此外，高性能低温冷冻库的价格通常高达数万美元，这无疑为小规模机构设置了进入门槛。液态氮补充、警报系统、校准和维护合约等持续成本进一步增加了总拥有成本。这些财务压力在电力供应不稳定、液态氮分销网络有限的中低收入地区尤为突出，阻碍了最佳实践系统的应用。因此，许多机构继续依赖老旧、低效的设备，这损害了样本的完整性，并限制了它们参与国际研究和先进治疗计画。

市场机会

利用人工智慧 (AI) 提升诊断能力－将人工智慧 (AI) 引入骨髓恶性肿瘤的诊断流程，为全球检测市场带来了巨大的成长机会。 AI 技术已展现出提升诊断准确性和速度的能力，尤其是在传统方法有其限制的复杂病例中。例如，AI 演算法在鑑别罕见血液癌症（如原发性纤维化和原发性血小板增多症）方面表现出色，为临床医生和病理学家提供了重要的支持。将 AI 整合到诊断工作流程中，能够提高诊断准确性、优化临床决策并提升病患管理效率。此外，AI 能够快速分析大量复杂的医疗数据，从而实现更快、更可靠的诊断，并有望加快临床试验的患者招募和新治疗方法的研发。随着医疗保健系统的不断发展，并越来越依赖 AI 技术来管理日益复杂的医疗数据，对 AI 驱动的诊断解决方案的需求预计将会成长。透过投资人工智慧技术或建立策略合作伙伴关係来增强这些能力的诊断公司，将在快速发展的生物保存市场中确立主导地位，并推动该领域的创新和成长。

全球生物保存市场可细分为多个关键领域，包括产品类型、应用、最终用户和区域市场。本报告透过分析哪些细分领域占据最大市场份额以及哪些细分领域具有成长潜力，为希望创新和拓展其生物保存产品及技术组合的企业提供宝贵的见解。

策略联盟、合资企业和扩张预计将在生物保存市场的成长中发挥核心作用。生物保存解决方案提供者、生物样本库、製药和生物技术公司以及研究机构之间的重大发展和合作关係构成了不断演变的市场动态的关键组成部分。

生物保存市场竞争异常激烈，许多成熟企业提供种类繁多的生物保存介质、设备和服务。主要市场参与企业正积极研发和推出先进的冷冻保存技术、自动化和数位化监控解决方案，以实现差异化竞争并巩固市场地位。

调查方法

市场设计与检验中的关键考虑因素与假设

  • 为了估算全球市场规模，我们考虑了 2024 年至 2035 年这段期间，其中 2024 年为基准年，2025 年至 2035 年为预测期。
  • 本研究的范围是基于来自各行业的专家的全面意见，包括生物样本库和基因库、製药和生物技术公司、细胞和基因治疗开发商、医院、学术研究机构和合约研究组织。
  • 预计未来生物保藏产品的市场份额将显着增长，该预测是基于对现有解决方案的历史分析。
  • 各公司的收入均根据其 2024 财政年度的年度报告收集。对于私人公司，公司收入根据一手调查数据、资金筹措历史、市场联繫状况和业务绩效进行估算。
  • 本报告基于现有市售生物保存介质和设备绘製了市场图。报告还识别并介绍了该领域提供关键产品和服务的主要企业。

主要市场参与企业及竞争格局概述

本次评选的公司是根据对公司覆盖范围、产品系列和市场渗透率的分析所得出的资讯而选定的。

该市场的主要企业包括：

  • BioLife Solutions, Inc.
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Azenta, Inc.
  • Bio-Techne
  • Cryoport Systems, LLC
  • Danaher Corporation (Cytiva)
  • PHC Corporation
  • Alpha Teknova, Inc.
  • Eppendorf SE
  • ThermoGenesis
  • OriGen Biomedical, Inc.
  • X-Therma, Inc.
  • STEMCELL Technologies
  • IC Biomedical, LLC

目录

执行摘要

第一章 全球生物保存市场：产业展望

  • 市场概览
    • 市场概览
    • 供应链分析
  • 市场趋势
    • 影响分析
    • 快速采用先进的冷冻保存技术
    • 人工智慧与实验室资讯管理系统在生物银行和生物检体管理中的整合日益加深
  • 监管状态
    • 我们
    • 欧洲
    • 亚太地区
  • 市场动态
    • 驱动因素、挑战和机会：评估当前和未来的影响
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章 产品类型

  • 概述
    • 装置
    • 培养基

第三章 应用

  • 概述
    • 研究用途
    • 治疗用途
    • 其他的

第四章 最终用户

  • 概述
    • 生物样本库和基因库
    • 医院
    • 製药和生物技术公司
    • 受託研究机构（CRO）
    • 其他的

第五章 区域

  • 区域概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第六章 竞争标竿分析与公司概况

  • 2023-2025年主要策略与发展
  • 2025年主要发展趋势分析（依公司划分）
  • 公司简介
    • BioLife Solutions, Inc.
    • Thermo Fisher Scientific Inc.
    • Sartorius AG
    • Azenta, Inc.
    • Bio-Techne
    • Cryoport Systems, LLC
    • Danaher Corporation (Cytiva)
    • PHC Corporation
    • Alpha Teknova, Inc.
    • Eppendorf SE
    • ThermoGenesis
    • OriGen Biomedical, Inc.
    • X-Therma, Inc.
    • STEMCELL Technologies
    • IC Biomedical, LLC

第七章调查方法

Product Code: BHL3415SA

This report can be delivered within 1 working day.

Introduction of the Biopreservation Market

The global biopreservation market, initially valued at $4,316.3 million in 2024, is projected to witness substantial growth, surging to $15,185.4 million by 2035, marking a remarkable compound annual growth rate (CAGR) of 12.61% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$4,631.8 Million
2035 Forecast$15,185.4 Million
CAGR12.61%

This growth is driven by the expanding adoption of cell and gene therapies, the rapid proliferation of biobanks and gene banks, and the increasing need for long-term preservation of high-value biological materials across research and clinical applications.

The biopreservation market is experiencing significant momentum due to the growing volume of biological samples generated from biomedical research, regenerative medicine, clinical trials, and advanced therapy manufacturing. Cells, tissues, blood, and genetic materials used in these applications require validated preservation solutions to maintain viability, stability, and functional integrity during storage, transportation, and downstream use. As personalized medicine, population genomics, and advanced therapeutics gain traction, reliable biopreservation has become a critical enabling infrastructure supporting these evolving healthcare and life sciences ecosystems.

Technological advancements are reshaping the biopreservation landscape, with innovations in cryopreservation media, controlled-rate freezing systems, automated and robotics-enabled cryogenic storage, and digitally integrated monitoring solutions improving sample quality, scalability, and regulatory compliance. Despite strong growth prospects, the market faces challenges such as high capital investment requirements, energy-intensive storage systems, and operational risks associated with freezer failures and cryogenic supply disruptions. Nevertheless, continued investments in biobanking infrastructure, regenerative medicine programs, and global cold-chain logistics are expected to sustain long-term market expansion.

Market Introduction

The global biopreservation market has evolved from conventional cold storage practices into a technologically advanced ecosystem supporting the preservation of cells, tissues, organs, and genetic material across research, clinical, and commercial environments. Market participants are increasingly focusing on developing high-performance biopreservation media, automation-ready cryogenic storage platforms, and digitally enabled monitoring systems to meet the rising quality, traceability, and compliance requirements of modern biobanking and advanced therapy workflows.

Strategic collaborations between biopreservation solution providers, biobanks, pharmaceutical and biotechnology companies, CDMOs, and academic research institutions are accelerating innovation and standardization across preservation workflows. As the scale and complexity of biospecimen collections continue to increase, biopreservation is emerging as a core infrastructure layer enabling precision medicine, cell and gene therapy manufacturing, and large-scale longitudinal research. These structural shifts are positioning biopreservation as a critical growth market within the global life sciences and healthcare ecosystem.

Industrial Impact

The global biopreservation market has witnessed significant industrial impact, driven by the rapid expansion of cell and gene therapies, large-scale biobanking initiatives, and the growing need for long-term storage of high-value biological materials. Key industry participants across biopreservation media, cryogenic storage systems, automation platforms, and cold-chain logistics play a central role in enabling reliable preservation of cells, tissues, blood, and genetic material used in research, clinical trials, and commercial manufacturing. These solutions are critical across applications such as cell and gene therapy development, regenerative medicine, biobanking, and precision medicine, where maintaining post-thaw viability, functionality, and sample integrity directly affects downstream outcomes.

Advances in cryopreservation media, controlled-rate freezing, automated and robotics-enabled cryogenic storage, and digitally integrated monitoring systems are improving operational efficiency, reducing sample loss, and strengthening regulatory compliance. By enabling consistent preservation across global research and manufacturing networks, biopreservation technologies support scalable clinical development, decentralized therapy manufacturing, and long-term longitudinal studies. The market's industrial impact is further amplified by its alignment with personalized medicine and advanced therapeutics, positioning biopreservation as a foundational infrastructure that underpins next-generation life sciences innovation and healthcare delivery.

Market Segmentation:

Segmentation 1: By Product

  • Media
  • Equipment's

Media Segment to Dominate the Biopreservation Market (by Product)

In terms of product, the media segment is expected to dominate the biopreservation market, accounting for a significant share due to its indispensable role in preserving the viability, stability, and functional integrity of biological materials, including cells, tissues, genetic material, and biopharmaceutical products used across cell and gene therapies, biobanking, and regenerative medicine. As the biotechnology and biopharmaceutical sectors continue to expand, alongside the rapid growth of cell-based and regenerative therapies, demand for high-performance biopreservation media is increasing steadily. Advanced therapies such as CAR-T and stem cell treatments rely heavily on cryopreservation to maintain cell quality throughout manufacturing, storage, and transport. Notably, a majority of FDA-approved cell and gene therapies depend on cryopreserved inputs or final products, underscoring the critical importance of optimizing post-thaw viability and functionality.

Segmentation 2: By Application

  • Research Applications
  • Therapeutic Applications
  • Other Applications

Research Application to Dominate the Biopreservation Market (by Application)

Research applications are expected to dominate the biopreservation market, driven by the growing volume of biomedical and genomic research, the rapid expansion of biobanks, and increasing activity in clinical trials and drug discovery. In research settings, biopreservation media and storage systems are essential to maintain the viability, stability, and molecular integrity of biological materials during long-term storage, transportation, and repeated experimental use. For example, in stem cell research, human pluripotent stem cells (hPSCs) are routinely preserved using specialized biopreservation media to retain pluripotency and differentiation potential after thawing, which is critical for regenerative medicine and developmental biology studies. Similarly, in genomic and population-based research, large-scale biobanks rely on validated biopreservation solutions to store DNA, RNA, tissues, and cells, ensuring sample consistency and suitability for longitudinal studies. As research programs scale globally and emphasize data reproducibility and sample quality, demand for reliable biopreservation solutions in research applications continues to remain strong, reinforcing this segment's leading position in the biopreservation market.

Segmentation 3: By End User

  • Biobanks and Genebanks
  • Hospitals
  • Pharmaceutical & Biotech Companies
  • Contract Research Organizations (CROs)
  • Others (Private Clinics, Academic Institutions, Government)

Biobanks and Genebanks to Dominate the Biopreservation Market (by End User)

Biobanks and gene banks are expected to dominate the biopreservation market due to their central role in genomic research, drug discovery, clinical trials, and personalized medicine. These institutions are responsible for the long-term storage of high-value biological materials, including cells, tissues, blood, and genetic samples, which form the foundation for disease research, biomarker identification, and therapeutic development. The rapid growth of genomic sequencing, population-scale studies, and biotechnology research has significantly increased the need for reliable biopreservation solutions that can maintain sample integrity, viability, and molecular stability over extended periods. In addition, sustained investments from governments, research consortia, and private organizations are driving the expansion of biobanks and gene banks globally, supporting regenerative medicine programs, large-scale epidemiological studies, and multicenter clinical trials. As these repositories continue to scale in size and complexity, demand for high-quality biopreservation media, cryogenic storage systems, and monitoring infrastructure is rising steadily.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

North America to Dominate the Biopreservation Market (by Region)

The global biopreservation market is experiencing strong growth, driven by expanding cell and gene therapy pipelines, large-scale biobanking initiatives, and increasing demand for long-term storage of high-value biological materials. North America is expected to remain the dominant region, supported by its advanced healthcare and research infrastructure, early adoption of cell and gene therapies, and significant investments in biobanks and regenerative medicine. The region's market size is projected to reach $6,243.3 million by 2035, underpinned by sustained demand for biopreservation media, cryogenic storage systems, and GMP-compliant cold-chain services. North America's leadership is further reinforced by the presence of leading biotechnology and pharmaceutical companies, well-established academic and clinical research institutions, and strong regulatory frameworks supporting advanced therapies. In addition, the growing volume of clinical trials, commercialization of CGTs, and expansion of national and private biobanking programs continue to drive long-term demand for reliable and scalable biopreservation solutions, solidifying the region's market dominance.

Recent Developments in the Biopreservation Market

  • In November 2025, BioLife Solutions, Inc. opened the Aby J. Mathew Center for Biopreservation Excellence. Located at the company's expanded headquarters in Bothell, the Center is named in honor of Aby J. Mathew, PhD, a founding team member of BioLife Solutions and the company's Executive Vice President and Chief Scientific Officer.
  • In October 2025, Cryoport, Inc. opened its new 55,000-square-foot Global Supply Chain Center in Louvres, France, strategically located near Charles de Gaulle Airport to enhance global delivery of advanced therapies. The state-of-the-art facility provides end-to-end, temperature-controlled supply chain solutions, offering unparalleled access and reliability for biologics and other temperature-sensitive materials.
  • In April 2025, BioLife Solutions, Inc. acquired the privately held PanTHERA CryoSolutions, Inc. ("PanTHERA"), a developer of advanced cryopreservation solutions built on proprietary Ice Recrystallization Inhibitor ("IRI") technology. This acquisition further solidifies BioLife's leadership in biopreservation, expands its portfolio of consumable solutions, and adds valuable scientific expertise to its management team.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Expansion of Cell and Gene Therapies and Regenerative Medicine: The rapid expansion of cell and gene therapies (CGTs) and regenerative medicine is a major structural driver of the biopreservation market. According to the 2024 Global Regulatory Report by the International Society for Cell and Gene Therapy (ISCT), more than 3,000 CGT programs are currently in development globally, with increasing late-stage clinical activity and regulatory approvals. These therapies depend heavily on cryopreserved materials across the entire value chain, including leukapheresis collections, engineered cell intermediates, viral vectors, cell banks, and frozen final drug products. Peer-reviewed studies demonstrate that cryopreserved inputs, such as leukapheresis material, can achieve post-thaw viability of 90% or higher while maintaining functional performance comparable to fresh material, validating cryopreservation as a non-inferior and scalable approach. As CGT manufacturing volumes rise and commercialization accelerates, demand is increasing for high-performance cryomedia, controlled-rate freezing, automated cryogenic storage, ultra-low-temperature and liquid nitrogen platforms, and GMP-compliant cold-chain logistics. This shift is transforming biopreservation into a core enabler of CGT development, manufacturing, and global distribution.

Market Challenges

High Capital and Operating Costs of Advanced Biopreservation Infrastructure: High capital and operating costs remain a major restraint on the biopreservation market, particularly for advanced cryogenic infrastructure. Ultra-low-temperature freezers, liquid nitrogen storage systems, controlled-rate freezers, and monitoring infrastructure require significant upfront investment and ongoing maintenance. ULT freezers are highly energy intensive, consuming up to 20 kWh per day, which translates into substantial annual electricity and HVAC costs, especially for facilities operating at scale. In addition, high-performance cryogenic freezers are typically priced in the tens of thousands of dollars, creating a clear entry barrier for smaller institutions. Recurring expenses for liquid nitrogen refills, alarm systems, calibration, and service contracts further increase total cost of ownership. These financial pressures are most acute in low- and middle-income regions, where unstable power supply and limited LN2 distribution networks restrict adoption of best-practice systems. As a result, many institutions continue to rely on aging, lower-performance equipment, which can compromise sample integrity and limit participation in global research and advanced therapy programs.

Market Opportunities

Utilizing Artificial Intelligence (AI) to Enhance Diagnostic Capabilities: The incorporation of artificial intelligence (AI) into the diagnostic process for hematologic malignancies represents a significant growth opportunity in the global testing market. AI technologies have demonstrated their ability to improve diagnostic accuracy and speed, particularly in complex cases where traditional methods may fall short. For example, AI-powered algorithms have shown exceptional performance in distinguishing between rare blood cancers such as primary myelofibrosis and essential thrombocythemia, providing critical support to clinicians and pathologists. The integration of AI into diagnostic workflows can enhance the precision of diagnoses, improve clinical decision-making, and streamline patient management. Moreover, AI's ability to analyze large volumes of complex medical data at high speeds allows for faster and more reliable diagnoses, which can facilitate quicker patient enrollment in clinical trials and accelerate the development of new treatments. As healthcare systems continue to evolve and rely on AI technologies to manage the growing complexity of medical data, the demand for AI-driven diagnostic solutions is expected to expand. Diagnostic companies investing in AI technologies and forming strategic collaborations to enhance these capabilities will be well-positioned to lead in the rapidly advancing Biopreservation market, driving both innovation and growth in the sector.

How can this report add value to an organization?

Product/Innovation Strategy: The global biopreservation market has been divided into several key segments, including product type, application, end users, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers valuable insights for organizations looking to innovate and expand their biopreservation product and technology offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the biopreservation market. Key developments and partnerships among biopreservation solution providers, biobanks, pharmaceutical and biotechnology companies, and research institutions form a significant part of the evolving market dynamics.

Competitive Strategy: The Biopreservation market is highly competitive, with numerous well-established players offering a wide range of biopreservation media, equipment, and services. Key market players are actively developing and adopting advanced cryopreservation technologies, automation, and digital monitoring solutions to differentiate themselves and strengthen their market position.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2035 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2025 to 2035 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts across various sectors, including biobanks and gene banks, pharmaceutical and biotechnology companies, cell and gene therapy developers, hospitals, academic research institutions, and CROs.
  • The market contribution of biopreservation products is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing commercially available biopreservation media, equipment. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in Biopreservation, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • BioLife Solutions, Inc.
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Azenta, Inc.
  • Bio-Techne
  • Cryoport Systems, LLC
  • Danaher Corporation (Cytiva)
  • PHC Corporation
  • Alpha Teknova, Inc.
  • Eppendorf SE
  • ThermoGenesis
  • OriGen Biomedical, Inc.
  • X-Therma, Inc.
  • STEMCELL Technologies
  • IC Biomedical, LLC

Table of Contents

Executive Summary

Scope and Definition

1 Global Biopreservation Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview
    • 1.1.2 Supply Chain Analysis
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Rapid Adoption of Advanced Cryopreservation Techniques
    • 1.2.3 Growing Integration of Artificial Intelligence and LIMS in Biobanking and Biospecimen Management
  • 1.3 Regulatory Landscape
    • 1.3.1 U.S.
      • 1.3.1.1 Regulatory Requirements for Biopreservation Media
      • 1.3.1.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
    • 1.3.2 Europe
      • 1.3.2.1 Regulatory Requirements for Biopreservation Media
      • 1.3.2.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 Japan
        • 1.3.3.1.1 Regulatory Requirements for Biopreservation Media
        • 1.3.3.1.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
      • 1.3.3.2 China
        • 1.3.3.2.1 Regulatory Requirements for Biopreservation Media
        • 1.3.3.2.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
  • 1.4 Market Dynamics
    • 1.4.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.4.2 Market Drivers
      • 1.4.2.1 Expansion of Cell and Gene Therapies and Regenerative Medicine
      • 1.4.2.2 Growing Investments and Funding for Biobanks
    • 1.4.3 Market Challenges
      • 1.4.3.1 High Capital and Operating Costs of Advanced Biopreservation Infrastructure
      • 1.4.3.2 Operational Risk from Freezer Failures and Cryogenic Supply Disruptions
    • 1.4.4 Market Opportunities
      • 1.4.4.1 Global Shift toward Automated, Robotics-Enabled Cryogenic Storage Systems

2 Product Type

  • 2.1 Overview
    • 2.1.1 Equipment
      • 2.1.1.1 Freezers
      • 2.1.1.2 Refrigerators
      • 2.1.1.3 Cryogenic Storage Systems
      • 2.1.1.4 Others
    • 2.1.2 Media
      • 2.1.2.1 Hypothermic Preservation Media
      • 2.1.2.2 Cryopreservation Media

3 Application

  • 3.1 Overview
    • 3.1.1 Research Applications
    • 3.1.2 Therapeutic Applications
    • 3.1.3 Other Applications

4 End User

  • 4.1 Overview
    • 4.1.1 Biobanks and Gene Banks
    • 4.1.2 Hospitals
    • 4.1.3 Pharmaceutical and Biotech Companies
    • 4.1.4 Contract Research Organizations (CROs)
    • 4.1.5 Others

5 Region

  • 5.1 Regional Summary
  • 5.2 North America
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 Market Sizing and Forecast
    • 5.2.5 U.S.
      • 5.2.5.1 Country Overview
      • 5.2.5.2 Market Sizing and Forecast
    • 5.2.6 Canada
      • 5.2.6.1 Country Overview
      • 5.2.6.2 Market Sizing and Forecast
  • 5.3 Europe
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 Market Sizing and Forecast
    • 5.3.5 U.K.
      • 5.3.5.1 Country Overview
      • 5.3.5.2 Market Sizing and Forecast
    • 5.3.6 Germany
      • 5.3.6.1 Country Overview
      • 5.3.6.2 Market Sizing and Forecast
    • 5.3.7 France
      • 5.3.7.1 Country Overview
      • 5.3.7.2 Market Sizing and Forecast
    • 5.3.8 Italy
      • 5.3.8.1 Country Overview
      • 5.3.8.2 Market Sizing and Forecast
    • 5.3.9 Spain
      • 5.3.9.1 Country Overview
      • 5.3.9.2 Market Sizing and Forecast
    • 5.3.10 Rest-of-the- Europe
      • 5.3.10.1 Country Overview
      • 5.3.10.2 Market Sizing and Forecast
  • 5.4 Asia Pacific
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 Market Sizing and Forecast
    • 5.4.5 China
      • 5.4.5.1 Country Overview
      • 5.4.5.2 Market Sizing and Forecast
    • 5.4.6 Japan
      • 5.4.6.1 Country Overview
      • 5.4.6.2 Market Sizing and Forecast
    • 5.4.7 India
      • 5.4.7.1 Country Overview
      • 5.4.7.2 Market Sizing and Forecast
    • 5.4.8 Australia
      • 5.4.8.1 Country Overview
      • 5.4.8.2 Market Sizing and Forecast
    • 5.4.9 South Korea
      • 5.4.9.1 Country Overview
      • 5.4.9.2 Market Sizing and Forecast
    • 5.4.10 Rest-of-the-Asia Pacific
      • 5.4.10.1 Country Overview
      • 5.4.10.2 Market Sizing and Forecast
  • 5.5 Rest-of-the-World
    • 5.5.1 Regional Overview
    • 5.5.2 Driving Factors for Market Growth
    • 5.5.3 Factors Challenging the Market
    • 5.5.4 Market Sizing and Forecast

6 Competitive Benchmarking and Company Profiles

  • 6.1 Key Strategies and Developments, 2023-2025
  • 6.2 Key Developments Analysis (by Company), 2025
  • 6.3 Company Profiles
    • 6.3.1 BioLife Solutions, Inc.
      • 6.3.1.1 Overview
    • 6.3.2 Thermo Fisher Scientific Inc.
      • 6.3.2.1 Overview
    • 6.3.3 Sartorius AG
      • 6.3.3.1 Overview
    • 6.3.4 Azenta, Inc.
      • 6.3.4.1 Overview
    • 6.3.5 Bio-Techne
      • 6.3.5.1 Overview
    • 6.3.6 Cryoport Systems, LLC
      • 6.3.6.1 Overview
    • 6.3.7 Danaher Corporation (Cytiva)
      • 6.3.7.1 Overview
    • 6.3.8 PHC Corporation
      • 6.3.8.1 Overview
    • 6.3.9 Alpha Teknova, Inc.
      • 6.3.9.1 Overview
    • 6.3.10 Eppendorf SE
      • 6.3.10.1 Overview
    • 6.3.11 ThermoGenesis
      • 6.3.11.1 Overview
    • 6.3.12 OriGen Biomedical, Inc.
      • 6.3.12.1 Overview
    • 6.3.13 X-Therma, Inc.
      • 6.3.13.1 Overview
    • 6.3.14 STEMCELL Technologies
      • 6.3.14.1 Overview
    • 6.3.15 IC Biomedical, LLC
      • 6.3.15.1 Overview

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Inclusion and Exclusion
    • 7.1.4 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Biopreservation Market (by Scenario), $Million, 2024, 2025, and 2035
  • Figure 2: Global Biopreservation Market, 2024 and 2035
  • Figure 3: Global Biopreservation Market (by Country), $Million, 2024
  • Figure 4: Global Biopreservation Market Snapshot
  • Figure 5: Global Biopreservation Market, $Million, 2024 and 2035
  • Figure 6: Biopreservation Market (by Product Type), $Million, 2024, 2028, and 2035
  • Figure 7: Biopreservation Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 8: Biopreservation Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 9: Biopreservation Market Segmentation
  • Figure 10: Application of AI in Biobanking
  • Figure 11: Global Biopreservation Market (by Product Type), $Million, 2024, 2028, and 2035
  • Figure 12: Global Biopreservation Market (by Equipment), $Million, 2024-2035
  • Figure 13: Global Biopreservation Market (Freezers), $Million, 2024-2035
  • Figure 14: Global Biopreservation Market (Refrigerators), $Million, 2024-2035
  • Figure 15: Global Biopreservation Market (Cryogenic Storage Systems), $Million, 2024-2035
  • Figure 16: Global Biopreservation Market (Others), $Million, 2024-2035
  • Figure 17: Global Biopreservation Market (by Media), $Million, 2024-2035
  • Figure 18: Global Biopreservation Market (Hypothermic Preservation Media), $Million, 2024-2035
  • Figure 19: Global Biopreservation Market (Cryopreservation Media), $Million, 2024-2035
  • Figure 20: Global Biopreservation Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 21: Global Biopreservation Market (Research Applications), $Million, 2024-2035
  • Figure 22: Global Biopreservation Market (Therapeutic Applications), $Million, 2024-2035
  • Figure 23: Global Biopreservation Market (Other Applications), $Million, 2024-2035
  • Figure 24: Global Biopreservation Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 25: Global Biopreservation Market (Biobanks and Gene Banks), $Million, 2024-2035
  • Figure 26: Global Biopreservation Market (Hospitals), $Million, 2024-2035
  • Figure 27: Global Biopreservation Market (Pharmaceutical and Biotech Companies), $Million, 2024-2035
  • Figure 28: Global Biopreservation Market (Contract Research Organizations (CROs)), $Million, 2024-2035
  • Figure 29: Global Biopreservation Market (Others), $Million, 2024-2035
  • Figure 30: North America Biopreservation Market, $Million, 2024-2035
  • Figure 31: U.S. Biopreservation Market, $Million, 2024-2035
  • Figure 32: Canada Biopreservation Market, $Million, 2024-2035
  • Figure 33: Europe Biopreservation Market, $Million, 2024-2035
  • Figure 34: U.K. Biopreservation Market, $Million, 2024-2035
  • Figure 35: Germany Biopreservation Market, $Million, 2024-2035
  • Figure 36: France Biopreservation Market, $Million, 2024-2035
  • Figure 37: Italy Biopreservation Market, $Million, 2024-2035
  • Figure 38: Spain Biopreservation Market, $Million, 2024-2035
  • Figure 39: Rest-of-Europe Biopreservation Market, $Million, 2024-2035
  • Figure 40: Asia-Pacific Biopreservation Market, $Million, 2024-2035
  • Figure 41: China Biopreservation Market, $Million, 2024-2035
  • Figure 42: Japan Biopreservation Market, $Million, 2024-2035
  • Figure 43: India Biopreservation Market, $Million, 2024-2035
  • Figure 44: Australia Biopreservation Market, $Million, 2024-2035
  • Figure 45: South Korea Biopreservation Market, $Million, 2024-2035
  • Figure 46: Rest-of-Asia-Pacific Biopreservation Market, $Million, 2024-2035
  • Figure 47: Rest-of-the-World Biopreservation Market, $Million, 2024-2035
  • Figure 48: Key Strategies and Developments, 2023-2025
  • Figure 49: Inclusion and Exclusion Criteria for the Global Biopreservation Market
  • Figure 50: Data Triangulation
  • Figure 51: Top-Down and Bottom-Up Approach
  • Figure 52: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Biopreservation Market (by Region), $Million, 2024-2035
  • Table 3: Key Strategies and Developments, 2025